ArticlePoultry science2026
Betulinic acid alleviates lipopolysaccharide-induced spleen injury by inhibiting the IL-17 signaling pathway in broilers.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Betulinic acid (BA), a naturally occurring pentacyclic triterpenoid compound widely distributed in various natural plant species, has immunomodulatory, anti-inflammatory, and antioxidant effects. Spleen injury triggers an immune stress response, leading to compromised systemic immunity and diminished production performance in broilers. However, the protective effects of BA against splenic injury in broilers and the underlying mechanisms remain unclear. This study aimed to investigate the protective effects and underlying mechanisms of dietary supplementation with BA against lipopolysaccharide (LPS)-induced spleen injury in broilers. After establishing a LPS-induced spleen injury model in broilers via intraperitoneal injection, we assessed BA's protective effects by analyzing splenic histomorphology, serum immunoglobulins, inflammatory cytokines, and redox status. Network pharmacology, transcriptomics, and molecular docking predicted the underlying mechanisms, which were further validated in vivo through RT-qPCR and Western blotting. Our results revealed that BA pretreatment significantly ameliorated splenic histopathological damage, increased serum concentrations of immunoglobulin, reduced the expression of inflammatory cytokines and enhanced antioxidant capacity in the spleen. Transcriptomic and network pharmacology analyses revealed that the IL-17 signaling pathway played a pivotal role in mediating BA's protective properties. Further molecular docking, molecular dynamics simulations, and in vivo experimental results indicated that BA bound stably to IL-17, inhibited the release of downstream inflammatory cytokines, maintained redox homeostasis and ultimately attenuated LPS-induced spleen injury in broilers. This study demonstrated that BA pretreatment ameliorated LPS-induced spleen injury by inhibiting the IL-17 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.